Cytokinetics Statistics
Total Valuation
Cytokinetics has a market cap or net worth of $10.63 billion. The enterprise value is $10.89 billion.
| Market Cap | 10.63B |
| Enterprise Value | 10.89B |
Important Dates
The last earnings date was Thursday, August 6, 2026, after market close.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Cytokinetics has 139.02 million shares outstanding. The number of shares has increased by 5.07% in one year.
| Current Share Class | 139.02M |
| Shares Outstanding | 139.02M |
| Shares Change (YoY) | +5.07% |
| Shares Change (QoQ) | +7.15% |
| Owned by Insiders (%) | 0.42% |
| Owned by Institutions (%) | 104.24% |
| Float | 133.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 157.06 |
| Forward PS | 44.92 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 160.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.66
| Current Ratio | 6.66 |
| Quick Ratio | 6.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.67 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -28.09% |
| Return on Invested Capital (ROIC) | -46.78% |
| Return on Capital Employed (ROCE) | -40.61% |
| Weighted Average Cost of Capital (WACC) | 6.39% |
| Revenue Per Employee | $100,550 |
| Profits Per Employee | -$1.33M |
| Employee Count | 673 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +124.13% in the last 52 weeks. The beta is 0.38, so Cytokinetics's price volatility has been lower than the market average.
| Beta (5Y) | 0.38 |
| 52-Week Price Change | +124.13% |
| 50-Day Moving Average | 78.69 |
| 200-Day Moving Average | 68.60 |
| Relative Strength Index (RSI) | 42.70 |
| Average Volume (20 Days) | 1,833,069 |
Short Selling Information
The latest short interest is 17.05 million, so 12.27% of the outstanding shares have been sold short.
| Short Interest | 17.05M |
| Short Previous Month | 17.57M |
| Short % of Shares Out | 12.27% |
| Short % of Float | 12.74% |
| Short Ratio (days to cover) | 6.62 |
Income Statement
In the last 12 months, Cytokinetics had revenue of $67.67 million and -$894.00 million in losses. Loss per share was -$7.18.
| Revenue | 67.67M |
| Gross Profit | -337.44M |
| Operating Income | -707.91M |
| Pretax Income | -894.00M |
| Net Income | -894.00M |
| EBITDA | -695.36M |
| EBIT | -707.91M |
| Loss Per Share | -$7.18 |
Balance Sheet
The company has $1.17 billion in cash and $1.42 billion in debt, with a net cash position of -$258.77 million or -$1.86 per share.
| Cash & Cash Equivalents | 1.17B |
| Total Debt | 1.42B |
| Net Cash | -258.77M |
| Net Cash Per Share | -$1.86 |
| Equity (Book Value) | -173.49M |
| Book Value Per Share | -1.25 |
| Working Capital | 1.03B |
Cash Flow
In the last 12 months, operating cash flow was -$555.45 million and capital expenditures -$25.26 million, giving a free cash flow of -$580.72 million.
| Operating Cash Flow | -555.45M |
| Capital Expenditures | -25.26M |
| Depreciation & Amortization | 12.55M |
| Net Borrowing | 314.99M |
| Free Cash Flow | -580.72M |
| FCF Per Share | -$4.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,046.12% |
| Pretax Margin | -1,321.12% |
| Profit Margin | n/a |
| EBITDA Margin | -1,027.58% |
| EBIT Margin | -1,046.12% |
| FCF Margin | n/a |
Dividends & Yields
Cytokinetics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.07% |
| Shareholder Yield | -5.07% |
| Earnings Yield | -8.41% |
| FCF Yield | -5.46% |
Analyst Forecast
The average price target for Cytokinetics is $108.85, which is 42.38% higher than the current price. The consensus rating is "Buy".
| Price Target | $108.85 |
| Price Target Difference | 42.38% |
| Analyst Consensus | Buy |
| Analyst Count | 22 |
| Revenue Growth Forecast (3Y) | 117.25% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on June 25, 2013. It was a reverse split with a ratio of 1:6.
| Last Split Date | Jun 25, 2013 |
| Split Type | Reverse |
| Split Ratio | 1:6 |
Scores
Cytokinetics has an Altman Z-Score of -1.25 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.25 |
| Piotroski F-Score | 1 |